The estimated Net Worth of Paul K. Audhya is at least 921 千$ dollars as of 22 August 2024. Dr Audhya owns over 5,000 units of KalVista Pharmaceuticals Inc stock worth over 920,634$ and over the last 3 years he sold KALV stock worth over 0$.
Dr has made over 10 trades of the KalVista Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of KALV stock worth 53,600$ on 22 August 2024.
The largest trade he's ever made was exercising 30,614 units of KalVista Pharmaceuticals Inc stock on 17 May 2024 worth over 328,182$. On average, Dr trades about 9,967 units every 53 days since 2021. As of 22 August 2024 he still owns at least 85,880 units of KalVista Pharmaceuticals Inc stock.
You can see the complete history of Dr Audhya stock trades at the bottom of the page.
Dr. Paul K. Audhya M.B.A., M.D. is the Chief Medical Officer at KalVista Pharmaceuticals Inc.
Paul's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over 74,823,944$ worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth 58,591,487$ . The most active insiders traders include Holdings A/S Novo、Capital Management, L.P.Ra ...、Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of 835,088$. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth 167,500$.
kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include: